Glioblastoma Market is segmented By Glioblastoma Epidemiology (Total Incident Cases of Glioblastoma, Gender-specific Incidence, Type-specific Incidence, Age-specific Inci ....
Market Size in USD
CAGR13.1%
Study Period | 2024 - 2031 |
Base Year of Estimation | 2023 |
CAGR | 13.1% |
Market Concentration | High |
Major Players | Bayer, Chimerix, Aivita Biomedical, Denovo Biopharma, Northwest Therapeutics |
The glioblastoma market is estimated to be valued at USD 1.15 Bn in 2024 and is expected to reach USD 2.74 Bn by 2031, growing at a compound annual growth rate (CAGR) of 13.1% from 2024 to 2031. With growing geriatric population and rising incidence rates of brain cancer, the market is poised to witness significant growth over the forecast period.
The market is driven by rising research into innovative treatment options and increasing approval of pipeline drugs. Major pharmaceutical players have ramped up R&D investments to develop targeted therapies and immunotherapies to treat Glioblastoma. Furthermore, growing awareness about the disease and better diagnosis is also contributing to the market growth. However, high cost of treatment continues to hinder widespread adoption.